Pilot Study of Atomoxetine To Enhance COgnition In Patients With Schizophrenia

Completed · Phase 4 · Has a placebo group

Conditions studied: Schizophrenia

In brief

Relationships between altered prefrontal cortical dopamine, norepinephrine and some cognitive impairments of schizophrenia supports and approach for pharmacological remediation of cognitive symptoms through manipulations of prefrontal cortical dopamine and norepinephrine. Atomoxetine, a selective norepinephrine re-uptake inhibitor, produces a widespread increase in brain norepinephrine and a secondary and selective increase in prefrontal dopamine. Given this, we are evaluating atomoxetine's cognitive effects in a pilot placebo controlled trial in patients with schizophrenia. Moreover, an fMRI investigation was undertaken to assess the neural mechanisms underlying the cognitive effects of atomoxetine.

Key facts

Study ID

NCT00488163

Run by

Research Foundation for Mental Hygiene, Inc.

People needed

20

Starts

2005-01-01

Expected to finish

2007-06-01

Last updated by the study team

2017-10-05

Who can join

Age: 18 and older, up to 65. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Subjects will be males and females between the ages of 18 and 65
• In good general medical health
• For patient subjects, a DSM-IV diagnosis of schizophrenia, any subtype
• Currently in remission or with stable, unchanging residual symptoms
• Receiving treatment with olanzapine, aripiprazole, risperidone, or quetiapine as their antipsychotic medication at a stable dose for a minimum of eight weeks.
• Able to complete neurocognitive tests
• Able to give informed consent. All subjects will be required to have at least an 8th grade reading level and/or a full-scale IQ of at least 85 as assessed by the Wide Range Achievement Test (WRAT).

You may not qualify if…

• Recent history (within previous year) of serious suicide, homicide, or physical violence, or current suicidal or homicidal thoughts
• Any axis I DSM-IV diagnosis in addition to schizophrenia or schizoaffective disorder except substance abuse in remission
• History of severe head trauma, neurological disorder, or medical illness which may contribute to the subjects' psychiatric symptoms or cognitive impairment
• Medical illness which requires taking any medication that has CNS activity which is known to impair cognition.
• Untreated or unstable hypertension.
• Coronary artery disease.
• Receiving concomitant anticholinergic drugs, antidepressants or mood stabilizers. If patient subjects are receiving benzodiazepines, they must be short or intermediate acting (e.g. alprazolam, lorazepam) and must be held 48 hours prior to cognitive testing
• Unable to give informed consent
• History of developmental disorder or less than an eighth

Where it is running

• Pilgrim Psychiatric Center — Brentwood, New York, United States
• Mount Sinai Hospital — New York, New York, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.